Safety and efficacy of nusinersen (Spinraza) in adults with spinal muscular atrophy (SMA) Type II/III
Latest Information Update: 11 Jun 2021
At a glance
- Drugs Nusinersen (Primary)
- Indications Spinal muscular atrophy
- Focus Adverse reactions; Therapeutic Use
- 11 Jun 2021 New trial record
- 22 Apr 2021 Results (n=40; as Sep 2020) presented at the 73rd Annual Meeting of the American Academy of Neurology